The Cerena Transcranial Magnetic Stimulator, the first medical device for the treatment of migraine headaches preceded with aura, has won regulatory approval in the United States.
On Friday, the US Food and Drug Administration (FDA) announced it had allowed marketing of the Cerena Transcranial Magnetic Stimulator (TMS), manufactured by eNeura Therapeutics of Sunnyvale, CA, for use under prescription, for the relief of pain caused by migraines that are preceded by an aura.
Migraine affects one in 10 people worldwide
A migraine is an intense pulsing or throbbing pain in part of the head, accompanied by nausea and sometimes vomiting, plus heightened sensitivity to light and sound. The debilitating condition can last from 4 up to 72 hours if not treated.
Migraines affect one in 10 people worldwide, with women three times more likely to experience them than men. Around one in three migraine sufferers also experiences an aura - a visual sensory or motor disturbance that precedes the headache itself.
No comments:
Post a Comment